Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Personalis (NASDAQ:PSNL) from a sell rating to a hold rating in a research report released on Saturday.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC boosted their target price on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Morgan Stanley raised their price target on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Lake Street Capital reissued a “buy” rating and issued a $11.00 price target on shares of Personalis in a report on Wednesday, November 5th. Finally, HC Wainwright boosted their target price on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Personalis has an average rating of “Moderate Buy” and a consensus target price of $10.71.

Personalis Price Performance

Personalis stock opened at $9.37 on Friday. The business has a fifty day moving average price of $9.23 and a 200-day moving average price of $7.59. The firm has a market capitalization of $832.06 million, a P/E ratio of -10.65 and a beta of 1.96. Personalis has a one year low of $2.83 and a one year high of $11.50.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. Sell-side analysts expect that Personalis will post -1.4 earnings per share for the current fiscal year.

Insider Activity at Personalis

In other news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the sale, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total value of $266,211.88. Following the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 134,481 shares of company stock worth $1,397,564. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently modified their holdings of PSNL. Kennedy Capital Management LLC lifted its holdings in Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the period. Aberdeen Group plc increased its holdings in Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Personalis by 165.6% in the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after purchasing an additional 851,422 shares in the last quarter. ARK Investment Management LLC raised its holdings in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after acquiring an additional 802,268 shares during the period. Finally, Blue Water Life Science Advisors LP lifted its holdings in Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after purchasing an additional 500,900 shares in the last quarter. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.